Monocyte-derived DC maturation strategies and related pathways: a transcriptional view

Abstract

Ex vivo production of highly-stimulator mature Dendritic Cells (DCs) for cellular therapy has been used to treat different pathological conditions with the aim of inducing a specific immune response. In the last decade several protocols have been developed to mature monocyte-derived DCs: each one has led to the generation of DCs showing different phenotypes and stimulatory abilities, but it is not yet known which one is the best for inducing effective immune responses. We grouped several different maturation protocols according to the downstream pathways they activated and reviewed the shared features at a transcriptomic level to reveal the potential of DCs matured by each protocol to develop Th polarized immune responses.

Human monocyte-derived dendritic cells from leukoreduction system chambers after plateletpheresis are functional in an in vitro co-culture assay with intestinal epithelial cells

“…PP-and BC-derived DC were assessed in co-culture systems with HT-29 cells and stimulated with LPS, a prototypical model of DC maturation (Castiello et al, 2011). Our results indicate that DC from PP behave similarly to BC-derived DC.…”

Preparation of dendritic cells for cancer immunotherapy

“…Индукция лигандами TLR приводит к созреванию ДК и активации продукции интерлейкинов ИЛ-12, ИЛ-23 и ИЛ-10. ЛПС взаимодействует с TLR4, что приводит к активации различных транскрипционных факторов, включая ядерный фактор-kB (NF-kB), p38 митоген активируемую протеинкиназу (p38 MAPK), c-Jun N-терминальную киназу (JNK) и протеинкиназы (ERK1/2) [34]. К третьему типу относятся лиганды рецептора CD40.…”

Dendritic cells derived from pluripotent stem cells: Potential of large scale production

“…+ cells are usually found in small numbers and a longer time is needed to generate sufficient DCs (14 d vs 7 d), thus monocyte-derived DCs have been used more often in clinical trials [42] . Production of autologous DCs involves the purification of monocytes from PBMCs, generating immature DCs from monocytes, and differentiating immature DCs into mature DCs [42,43] .…”

“…Production of autologous DCs involves the purification of monocytes from PBMCs, generating immature DCs from monocytes, and differentiating immature DCs into mature DCs [42,43] . For clinical use, a scalable culture system that meets current Good Manufacturing Practices (cGMP) guidelines is required.…”